Search Results - "Vivier, N"

  • Showing 1 - 17 results of 17
Refine Results
  1. 1

    The pharmacokinetics of idraparinux, a long‐acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials by VEYRAT‐FOLLET, C., VIVIER, N., TRELLU, M., DUBRUC, C., SANDERINK, G. J.

    Published in Journal of thrombosis and haemostasis (01-04-2009)
    “…Background: Idraparinux, a long‐acting synthetic pentasaccharide, is a specific antithrombin‐dependent inhibitor of activated factor X that has been…”
    Get full text
    Journal Article
  2. 2

    Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer by Bruno, R, Hille, D, Riva, A, Vivier, N, ten Bokkel Huinnink, W W, van Oosterom, A T, Kaye, S B, Verweij, J, Fossella, F V, Valero, V, Rigas, J R, Seidman, A D, Chevallier, B, Fumoleau, P, Burris, H A, Ravdin, P M, Sheiner, L B

    Published in Journal of clinical oncology (01-01-1998)
    “…The population pharmacokinetic/pharmacodynamic (PK/PD) approach was prospectively integrated in the clinical development of docetaxel to assess the PK profile…”
    Get more information
    Journal Article
  3. 3

    Pharmacokinetics of sparfloxacin in patients with renal impairment by FILLASTRE, J. P, MONTAY, G, BRUNO, R, ETIENNE, I, DHIB, M, VIVIER, N, LE ROUX, Y, GUIMART, C, GAY, G, SCHOTT, D

    Published in Antimicrobial Agents and Chemotherapy (01-04-1994)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  4. 4
  5. 5

    α-1-Acid Glycoprotein As an Independent Predictor for Treatment Effects and a Prognostic Factor of Survival in Patients with Non-small Cell Lung Cancer Treated with Docetaxel by BRUNO, René, OLIVARES, Robert, BERILLE, Jocelyne, CHAIKIN, Philip, VIVIER, Nicole, HAMMERSHAIMB, Luz, RHODES, Gerald R, RIGAS, James R

    Published in Clinical cancer research (01-03-2003)
    “…Purpose: To identify predictors of treatment outcome and survival in patients with non-small cell lung cancer (NSCLC) treated with docetaxel. Experimental…”
    Get full text
    Journal Article
  6. 6

    A population pharmacokinetic model for docetaxel (Taxotere): model building and validation by Bruno, R, Vivier, N, Vergniol, J C, De Phillips, S L, Montay, G, Sheiner, L B

    “…A sparse sampling strategy (3 samples per patient, 521 patients) was implemented in 22 Phase 2 studies of docetaxel (Taxotere) at the first treatment cycle for…”
    Get more information
    Journal Article
  7. 7

    Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel by Bruno, R, Vivier, N, Veyrat-Follet, C, Montay, G, Rhodes, G R

    Published in Investigational new drugs (01-05-2001)
    “…The population approach has been implemented prospectively in the clinical development of docetaxel (Taxotere). Overall 640 patients were evaluable for the…”
    Get full text
    Journal Article
  8. 8

    Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina and non‐ST‐segment elevation myocardial infarction by Bruno, René, Baille, Pascale, Retout, Sylvie, Vivier, Nicole, Veyrat‐Follet, Christine, Sanderink, Ger‐Jan, Becker, Richard, Antman, Elliott M.

    Published in British journal of clinical pharmacology (01-10-2003)
    “…Aims  A major concern with any antithrombotic therapy is an increase in the risk of haemorrhage. The aim of this study was to analyse population…”
    Get full text
    Journal Article
  9. 9

    Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis by Bruno, René, Vivier, Nicole, Montay, Guy, Liboux, Aim éLe, Powe, Larry K., Delumeau, Jean‐Christophe, Rhodes, Gerald R.

    Published in Clinical pharmacology and therapeutics (01-11-1997)
    “…Objectives To characterize the population pharmacokinetic of riluzole in patients with amyotrophic lateral sclerosis (ALS). Methods One hundred patients with…”
    Get full text
    Journal Article
  10. 10
  11. 11
  12. 12
  13. 13

    COMMUNAUX ET VITALITÉ COMMUNAUTAIRE EN FRANCE À LA FIN DE L'ANCIEN RÉGIME ET PENDANT LA RÉVOLUTION by VIVIER, NADINE

    “…Malgré une offensive menée en deux temps (1760-1780 puis 1789-1794), les biens communaux en France ont subsisté en grande partie. Seules pouvaient les…”
    Get full text
    Journal Article
  14. 14
  15. 15

    Les biens communaux du Briançonnais aux XVIIIe et XIXe siècles by Vivier, Nadine

    Published in Études rurales (1990)
    “…Communal property in the Briangon area during the 18th and 19th centuries The Briançon area in the Alps managed to keep 80% of its land as property of the…”
    Get full text
    Journal Article
  16. 16
  17. 17